Morgan Stanley analyst Erin Wright upgraded Heska to Equal Weight from Underweight with a price target of $120, up from $58, after Mars announced it will acquire the company for $120 per share. The deal will combine the third largest point of care pet diagnostics player with Mars’ leading reference laboratory services and veterinary hospital businesses, says the firm, which views other bidders as "unlikely."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on HSKA:
- Heska downgraded to Neutral from Buy at Alliance Global Partners
- Mars to Acquire Heska, Global Provider of Advanced Veterinary Diagnostic and Specialty Solutions
- Mars to acquire Heska for $120.00 per share
- Heska price target lowered to $150 from $165 at Piper Sandler
- Heska price target raised to $129 from $119 at Alliance Global Partners
